Supports translational projects that turn biological/mechanistic insights into new targets and approaches for primary cancer prevention. Emphasis on hypothesis-driven precision prevention, biomarker/surrogate endpoint development, and interdisciplinary collaboration across biology, genetics, immunology, drug development, and prevention science.
Eligibility Criteria:
-
Lead applicant based at a UK university/medical school/hospital/research institute; some postdoctoral (or equivalent) experience.
-
All career stages welcome; early-career leads encouraged (include an established co-applicant for mentorship).
-
Host institution approval required and capacity to support the work.
-
Strongly encouraged: UK multi-institution teams; optional co-funded, true partnerships with US (ACS) or Canada (CCS) leads.
-
Closed round: applicants must contact [email protected] for an informal, confidential eligibility discussion before applying.
Funding Details:
-
Amount: Flexible, ~GBP 100,000–600,000 (indexation per policy).
-
Duration: Up to 5 years.
-
Use of funds: PDRA/technical staff + associated running costs; equipment up to GBP 50,000 (contact funder if more needed).
-
Pilot/high-risk, high-reward (~GBP 100,000 over 1 year).
-
Longer-term with strong prelim data (up to GBP 600,000 over 3–5 years).
Project types:
-
-
Salary: One early-/mid-career investigator may request salary (must meet policy and discuss in advance).
-
Co-funding options:
-
ACS (USA): UK costs via this scheme (≤ GBP 600,000) + ACS covers US costs (≤ USD 946,000 incl. 10% indirects).
-
CCS (Canada): UK costs via this scheme (≤ GBP 600,000) + CCS covers Canada costs (≤ CAD 1,000,000 direct).
-
Deadline:
-
Next full application deadline for May 2026 committee review: 4 December 2025.
-
Scheme reviewed twice per year (contact at least one month before deadline).
Where to go for further information:
-
Pre-application/eligibility discussion: [email protected].